548 related articles for article (PubMed ID: 25536589)
41. Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response.
Diaz-Botero S; Espinosa-Bravo M; Gonçalves VR; Esgueva-Colmenarejo A; Peg V; Perez J; Cortes J; Rubio IT
Ann Surg Oncol; 2016 Nov; 23(12):3831-3837. PubMed ID: 27357178
[TBL] [Abstract][Full Text] [Related]
42. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.
Bulent Akinci M; Algin E; Inal A; Odabas H; Berk V; Coskun U; Uyeturk U; Isikdogan A; Aksoy S; Civelek B; Sevinc A; Buyukberber S
J BUON; 2013; 18(2):314-20. PubMed ID: 23818340
[TBL] [Abstract][Full Text] [Related]
43. An overview of triple-negative breast cancer.
Kumar P; Aggarwal R
Arch Gynecol Obstet; 2016 Feb; 293(2):247-69. PubMed ID: 26341644
[TBL] [Abstract][Full Text] [Related]
44. Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study.
Morgan E; Suresh A; Ganju A; Stover DG; Wesolowski R; Sardesai S; Noonan A; Reinbolt R; VanDeusen J; Williams N; Cherian MA; Li Z; Young G; Palettas M; Stephens J; Liu J; Luff A; Ramaswamy B; Lustberg M
World J Surg Oncol; 2020 Jan; 18(1):11. PubMed ID: 31937323
[TBL] [Abstract][Full Text] [Related]
45. [Evaluation of the predictive effect of PD-L1 expression on survival in early triple-negative breast cancer].
Yue J; Wang X; Zhu AJ; Wang DY; Gao SL; Hu NL; Si YR; Zheng FC; Ju J; Wang Z; Yuan P
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):948-954. PubMed ID: 37968080
[No Abstract] [Full Text] [Related]
46. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea.
Park YH; Karantza V; Calhoun SR; Park S; Lee S; Kim JY; Yu JH; Kim SW; Lee JE; Nam SJ; Aktan G; Marsico M
Breast Cancer Res Treat; 2021 Oct; 189(3):653-663. PubMed ID: 34487293
[TBL] [Abstract][Full Text] [Related]
47. Early Stage Triple-Negative Breast Cancer: Imaging and Clinical-Pathologic Factors Associated with Recurrence.
Bae MS; Moon HG; Han W; Noh DY; Ryu HS; Park IA; Chang JM; Cho N; Moon WK
Radiology; 2016 Feb; 278(2):356-64. PubMed ID: 26230976
[TBL] [Abstract][Full Text] [Related]
48. Predictive factors and patterns of recurrence in patients with triple negative breast cancer.
Steward L; Conant L; Gao F; Margenthaler JA
Ann Surg Oncol; 2014 Jul; 21(7):2165-71. PubMed ID: 24558065
[TBL] [Abstract][Full Text] [Related]
49. A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.
Tzikas AK; Nemes S; Linderholm BK
Breast Cancer Res Treat; 2020 Aug; 182(3):643-654. PubMed ID: 32524352
[TBL] [Abstract][Full Text] [Related]
50. Outcome of pN0 Triple-Negative Breast Cancer with or without Lymph Node Irradiation: A Single Institution Experience.
Khalifa J; Duprez-Paumier R; Filleron T; Lacroix Triki M; Jouve E; Dalenc F; Massabeau C
Breast J; 2016 Sep; 22(5):510-9. PubMed ID: 27261365
[TBL] [Abstract][Full Text] [Related]
51. Prognostic impact of triple negative phenotype in conservatively treated breast cancer.
Barbieri V; Sanpaolo P; Genovesi D
Breast J; 2011; 17(4):377-82. PubMed ID: 21615820
[TBL] [Abstract][Full Text] [Related]
52. Traditional and new prognosticators in breast cancer: Nottingham index, Mib-1 and estrogen receptor signaling remain the best predictors of relapse and survival in a series of 289 cases.
Megha T; Neri A; Malagnino V; Caruso S; Onorati M; Roviello F; Tosi P
Cancer Biol Ther; 2010 Feb; 9(4):266-73. PubMed ID: 20026902
[TBL] [Abstract][Full Text] [Related]
53. Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1-2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy.
Lai SF; Chen YH; Kuo WH; Lien HC; Wang MY; Lu YS; Lo C; Kuo SH; Cheng AL; Huang CS
Ann Surg Oncol; 2016 Nov; 23(12):3860-3869. PubMed ID: 27436202
[TBL] [Abstract][Full Text] [Related]
54. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
[TBL] [Abstract][Full Text] [Related]
55. Post-operative radiotherapy is beneficial for T1/T2 triple negative breast cancer patients with four or more positive lymph nodes.
Chen L; Zhang J; Chen J; Liu L; Liang L; Shangguan Z; Wang D
Oncotarget; 2017 Jun; 8(26):42917-42925. PubMed ID: 28476034
[TBL] [Abstract][Full Text] [Related]
56. High tumor budding count is associated with adverse clinicopathologic features and poor prognosis in breast carcinoma.
Li X; Wei B; Sonmez C; Li Z; Peng L
Hum Pathol; 2017 Aug; 66():222-229. PubMed ID: 28655638
[TBL] [Abstract][Full Text] [Related]
57. Triple Negative Breast Cancer: 10-Year Survival Update of The Applied Treatment Strategy in Kuwait.
Fayaz S; Demian GA; El-Sherify M; Eissa H; Aziz M; Abuzallouf S
Gulf J Oncolog; 2019 Jan; 1(29):53-59. PubMed ID: 30957764
[TBL] [Abstract][Full Text] [Related]
58. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
[TBL] [Abstract][Full Text] [Related]
59. Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (Ionta MT; Atzori F; Deidda MC; Pusceddu V; Palmeri S; Frau B; Murgia M; Barca M; Minerba L; Massidda B
Oncologist; 2009 Nov; 14(11):1051-60. PubMed ID: 19897535
[TBL] [Abstract][Full Text] [Related]
60. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
